Effects of dilazep on human platelets and rat vascular tissue: in vitro studies on platelet aggregation, and arachidonic acid oxidation.
The "in vitro" effects of Dilazep on platelet aggregation and arachidonic acid oxidation in platelets and vessel wall were studied. Dilazep exerted a clearcut inhibitory effect on platelet aggregation induced by several stimuli. In addition, the compound completely suppressed malondialdehyde production by platelets elicited by collagen and thrombin, in a dose-dependent fashion. The evaluation of Dilazep effects on the in vitro release of prostacyclin-like material by rat aortic tissue did not provide any indication about an interference of the drug on the generation of endogenous antiaggregatory material.
D000818:Animals; D001011:Aorta / Q000378:metabolism; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000378:metabolism*; D001381:Azepines / Q000494:pharmacology*; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D001808:Blood Vessels / Q000187:drug effects* / Q000378:metabolism; D004109:Dilazep / Q000494:pharmacology*; D011464:Epoprostenol / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D010084:Oxidation-Reduction; D010974:Platelet Aggregation / Q000187:drug effects; D051381:Rats
D001095:Arachidonic Acids; D001381:Azepines; D016718:Arachidonic Acid; D008315:Malondialdehyde; D011464:Epoprostenol; D004109:Dilazep